Total submissions: 6
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Invitae | RCV000234726 | SCV000289237 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2022-11-02 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 355 of the POLE protein (p.Lys355Arg). This variant is present in population databases (rs141396559, gnomAD 0.05%). This variant has not been reported in the literature in individuals affected with POLE-related conditions. ClinVar contains an entry for this variant (Variation ID: 240374). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POLE protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Gene |
RCV000485791 | SCV000572894 | uncertain significance | not provided | 2023-08-02 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 20951805) |
| Ambry Genetics | RCV000575355 | SCV000671377 | likely benign | Hereditary cancer-predisposing syndrome | 2024-01-23 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
| Fulgent Genetics, |
RCV000763816 | SCV000894733 | uncertain significance | Colorectal cancer, susceptibility to, 12; Facial dysmorphism-immunodeficiency-livedo-short stature syndrome | 2018-10-31 | criteria provided, single submitter | clinical testing | |
| Division of Medical Genetics, |
RCV000234726 | SCV001434297 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2020-05-05 | criteria provided, single submitter | clinical testing | To our knowledge, this sequence variant has not been previously reported in the literature. This variant has an overall allele frequency of 0.00005 in the Broad Institute gnomAD Browser (https://gnomad.broadinstitute.org/), and is more common in populations of African ancestry. This variant is in the exonuclease domain of the protein where other pathogenic sequence variants have been found. In silico analyses indicate that this variant may not alter protein structure/function. Thus, it is unknown at this time whether this variant increases cancer risk. BP4; PM1 |
| Baylor Genetics | RCV000234726 | SCV004203528 | uncertain significance | Colorectal cancer, susceptibility to, 12 | 2024-03-25 | criteria provided, single submitter | clinical testing |